-
Mashup Score: 1Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML - 11 hour(s) ago
Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML - 4 day(s) ago
Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML @ASH_hematology #ASH24 #lymsm #leusm https://t.co/NjjqH6S4PD
-
-
Mashup Score: 1Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia - 8 day(s) ago
Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia @ASH_hematology #ASH24 #lymsm #leusm https://t.co/YVlbgQtmJd
-
-
Mashup Score: 1Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia - 11 day(s) ago
Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia @ASH_hematology #ASH24 #lymsm #leusm https://t.co/YVlbgQtmJd
-
-
Mashup Score: 1Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia - 23 day(s) ago
Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia @ASH_hematology #ASH24 #lymsm #leusm https://t.co/YVlbgQtmJd
-
Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML @ASH_hematology #ASH24 #lymsm #leusm https://t.co/NjjqH6S4PD